Literature DB >> 16245074

Interleukin 6 and 12, alanine aminotransferase activity, and HCV viral load in children with chronic hepatitis C treated with interferon and ribavirin.

Arleta Kowala-Piaskowska1, Iwona Mozer-Lisewska, Magdalena Figlerowicz, Ludomiła Machowska, Wojciech Słuzewski.   

Abstract

The response to viral infections is mediated through the co-operation of cellular and humoral mechanisms. The aim of this study was to seek the correlation between IL-6 and IL-12 level, HCV viral load, ALT activity during the 48-week treatment with interferon-alpha-2b (IFN-alpha-2b) combined with ribavirin in children with diagnosed CHC and to search their influence on positive response to treatment. The group of 27 children with CHC was enrolled into this study. The children were treated with interferon-alpha and ribavirin in the course of 48-week therapy. The results show that both ALT activity and the viral load at the time of implementation of treatment with IFN-alpha and ribavirin is an important prognostic tool when treating children. It has been shown that the levels of IL-6 do not bear any significant prognostic importance to the implemented therapy, yet the increase of IL-12 levels in the 24th week of the treatment may be of prognostic value and may point out the possible elimination of HCV-RNA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16245074     DOI: 10.1007/s10753-004-6642-y

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  17 in total

1.  Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment.

Authors:  M Malaguarnera; I Di Fazio; A Laurino; L Ferlito; M Romano; B A Trovato
Journal:  Int J Clin Pharmacol Ther       Date:  1997-09       Impact factor: 1.366

2.  Immunity to hepatitis C virus: a further piece of the puzzle.

Authors:  M Battegay
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

3.  Combination therapy of chronic hepatitis C: an important step but not the final goal!

Authors:  H Wedemeyer; W H Caselmann; M P Manns
Journal:  J Hepatol       Date:  1998-12       Impact factor: 25.083

4.  Prognosis of chronic hepatitis C patients correlates with circulating monocyte/macrophage function.

Authors:  M Yamashiki; A Nishimura; H Suzuki
Journal:  Clin Sci (Lond)       Date:  1997-10       Impact factor: 6.124

Review 5.  Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection.

Authors:  V Carreño; J A Quiroga
Journal:  J Viral Hepat       Date:  1997       Impact factor: 3.728

6.  Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.

Authors:  S Ampurdanés; E Olmedo; M D Maluenda; X Forns; F X López-Labrador; J Costa; J M Sánchez-Tapias; M T de Anta; J Rodés
Journal:  J Hepatol       Date:  1996-12       Impact factor: 25.083

Review 7.  The immunopathogenesis of hepatitis C virus infection.

Authors:  D R Nelson
Journal:  Clin Liver Dis       Date:  2001-11       Impact factor: 6.126

Review 8.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.

Authors:  G Trinchieri
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

9.  Induction of interleukin-6 by interferon alfa and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C.

Authors:  N Ito; S Kawata; S Tamura; S Kiso; H Tsushima; Y Maeda; E Yamasaki; T Igura; Y Matsuzawa
Journal:  Hepatology       Date:  1996-04       Impact factor: 17.425

10.  Differential regulation of interleukin-12 (IL-12), tumor necrosis factor alpha, and IL-1 beta production in human myeloid leukemia cell lines and peripheral blood mononuclear cells.

Authors:  M Kubin; J M Chow; G Trinchieri
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.